DK1476138T3 - Formuleringer med modificeret frigivelse af mindst én form af tramadol - Google Patents

Formuleringer med modificeret frigivelse af mindst én form af tramadol

Info

Publication number
DK1476138T3
DK1476138T3 DK03743147.5T DK03743147T DK1476138T3 DK 1476138 T3 DK1476138 T3 DK 1476138T3 DK 03743147 T DK03743147 T DK 03743147T DK 1476138 T3 DK1476138 T3 DK 1476138T3
Authority
DK
Denmark
Prior art keywords
tramadol
release formulations
modified release
polyglycol
melting point
Prior art date
Application number
DK03743147.5T
Other languages
English (en)
Inventor
Pawan Seth
Paul J Maes
Original Assignee
Valeant Internat Barbados Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27765948&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1476138(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Valeant Internat Barbados Srl filed Critical Valeant Internat Barbados Srl
Application granted granted Critical
Publication of DK1476138T3 publication Critical patent/DK1476138T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Paints Or Removers (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DK03743147.5T 2002-02-21 2003-02-21 Formuleringer med modificeret frigivelse af mindst én form af tramadol DK1476138T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35785102P 2002-02-21 2002-02-21
PCT/US2003/004866 WO2003072025A2 (en) 2002-02-21 2003-02-21 Modified release formulations of at least one form of tramadol

Publications (1)

Publication Number Publication Date
DK1476138T3 true DK1476138T3 (da) 2012-02-20

Family

ID=27765948

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03743147.5T DK1476138T3 (da) 2002-02-21 2003-02-21 Formuleringer med modificeret frigivelse af mindst én form af tramadol

Country Status (15)

Country Link
US (4) US7780987B2 (da)
EP (2) EP1476139B1 (da)
JP (3) JP5069395B2 (da)
AT (1) ATE536173T1 (da)
AU (2) AU2003211145B2 (da)
CA (2) CA2476201C (da)
CY (1) CY1112517T1 (da)
DK (1) DK1476138T3 (da)
ES (2) ES2627842T3 (da)
MX (2) MXPA04008100A (da)
NO (1) NO20043913L (da)
NZ (2) NZ535456A (da)
PT (1) PT1476138E (da)
SI (1) SI1476138T1 (da)
WO (2) WO2003072025A2 (da)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
MXPA04008100A (es) 2002-02-21 2005-06-17 Biovail Lab Int Srl Formulaciones de liberacion modificada de al menos una forma de tramadol.
US8128957B1 (en) * 2002-02-21 2012-03-06 Valeant International (Barbados) Srl Modified release compositions of at least one form of tramadol
US8323692B2 (en) * 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7413749B2 (en) 2003-03-11 2008-08-19 Purdue Pharma L.P. Titration dosing regimen for controlled release tramadol
EP1905435A3 (en) * 2003-03-11 2008-05-14 Euro-Celtique S.A. Titration dosing regimen for controlled release tramadol
WO2005016318A1 (en) * 2003-08-08 2005-02-24 Biovail Laboratories Inc. Modified-release tablet of bupropion hydrochloride
US7206632B2 (en) * 2003-10-02 2007-04-17 Medtronic, Inc. Patient sensory response evaluation for neuromodulation efficacy rating
US20050074469A1 (en) * 2003-10-03 2005-04-07 Charles Signorino Stable lipophilic emulsions for acrylic coating and method of making
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
US20050084531A1 (en) * 2003-10-16 2005-04-21 Jatin Desai Tablet with aqueous-based sustained release coating
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US8586085B2 (en) * 2004-11-08 2013-11-19 Biokey, Inc. Methods and formulations for making pharmaceutical compositions containing bupropion
US20060099262A1 (en) * 2004-11-08 2006-05-11 Biokey, Inc. Methods and formulations for making controlled release oral dosage form
WO2006048895A1 (en) * 2004-11-08 2006-05-11 Rubicon Research Pvt. Ltd. Aqueous pharmaceutical coating
US20060099261A1 (en) * 2004-11-08 2006-05-11 Biokey, Inc. Methods and formulations for making controlled release oral dosage form
ZA200711123B (en) 2005-06-27 2009-08-26 Biovail Lab Int Srl Modified-release formulations of a bupropion salt
NZ565108A (en) * 2005-07-07 2011-10-28 Farnam Co Inc Sustained release pharmaceutical compositions for highly water soluble drugs
US8778395B2 (en) * 2005-08-11 2014-07-15 Andrx Labs, Llc Diltiazem controlled release formulation and method of manufacture
WO2007048219A2 (en) 2005-09-09 2007-05-03 Labopharm Inc. Sustained drug release composition
WO2007063946A1 (ja) * 2005-11-30 2007-06-07 Fujifilm Ri Pharma Co., Ltd. アミロイドの凝集及び／又は沈着に起因する疾患の診断薬及び治療薬
ES2279715B1 (es) * 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
EP2540725A1 (de) 2006-05-04 2013-01-02 Boehringer Ingelheim International GmbH Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
US20070264335A1 (en) * 2006-05-09 2007-11-15 Sherman Bernard C Modified release tablets comprising tramadol
CZ300698B6 (cs) * 2006-06-16 2009-07-22 Zentiva, A. S. Tableta s obsahem metforminu
US20080031927A1 (en) * 2006-07-11 2008-02-07 Catani Steven J Solid oral dosage vitamin and mineral compositions
US8703191B2 (en) * 2006-07-25 2014-04-22 Intelgenx Corp. Controlled-release pharmaceutical tablets
US7674479B2 (en) 2006-07-25 2010-03-09 Intelgenx Corp. Sustained-release bupropion and bupropion/mecamylamine tablets
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
AR071375A1 (es) * 2008-04-22 2010-06-16 Solvay Pharm Gmbh Formulaciones para ingredientes farmaceuticos activos de permeabilidad deficiente, proceso de preparacion y producto
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
CA2638240C (en) 2008-08-29 2010-02-02 Alexander Macgregor Method of treating dysglycemia and glucose excursions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP5685550B2 (ja) 2009-02-13 2015-03-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｇｌｔ２阻害剤、ｄｐｐ−ｉｖ阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) * 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
WO2011090725A2 (en) * 2009-12-29 2011-07-28 Impax Laboratories, Inc. Gastroretentive solid oral dosage forms with swellable hydrophilic polymer
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) * 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
FI126168B (en) 2012-09-18 2016-07-29 Novaldmedical Ltd Oy A method for coating pharmaceutical substrates
US9532946B2 (en) 2012-11-20 2017-01-03 Intervet Inc. Manufacturing of semi-plastic pharmaceutical dosage units
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
JP2018043198A (ja) * 2016-09-15 2018-03-22 トヨタ自動車株式会社 粉粒体混合機
ES3037252T3 (en) * 2016-12-15 2025-09-30 Spero Therapeutics Inc Novel tebipenem pivoxil immediate and modified release oral dosage forms
CN111712235A (zh) 2018-01-16 2020-09-25 应用材料公司 金属氧化物包封的药物组合物及其制备方法
DE102018001601A1 (de) * 2018-03-01 2019-09-05 Mann+Hummel Gmbh Koaleszenzabscheider, insbesondere zur Verwendung in einem Kompressordruckluftsystem, Kompressordruckluftsystem sowie Verwendung eines Koaleszenzabscheiders
MX2022001975A (es) 2019-08-16 2022-03-11 Applied Molecular Transport Inc Composiciones, formulaciones y produccion y purificacion de interleucinas.
EP4021421A4 (en) 2019-08-27 2023-05-10 Applied Materials, Inc. VAPOR PHASE COATINGS FOR PHARMACEUTICAL SOLUTION CONTROL
EP4021423A4 (en) 2019-08-27 2023-11-08 Applied Materials, Inc. Vapor phase coating technology for pharmaceutical abuse deterrent formulations
TWI870622B (zh) 2020-10-02 2025-01-21 美商應用材料股份有限公司 製備氧化矽塗佈藥品的低溫處理
WO2022104087A1 (en) 2020-11-11 2022-05-19 Spero Therapeutics, Inc. High dosage tebipenem pivoxil tablet formulation
WO2023056304A1 (en) 2021-09-30 2023-04-06 Applied Materials, Inc. Low temperature silicon oxide coating for pharmaceutical applications

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3097144A (en) * 1960-10-14 1963-07-09 Upjohn Co Heat-cured, polymeric, medicinal dosage film coatings containing a polyvinylpyrrolidone copolymer, polyethenoid acid, and polyethylene glycol
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
JPS63215620A (ja) * 1987-03-03 1988-09-08 Nippon Soda Co Ltd 徐放性製剤
GB8707416D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
JP2700662B2 (ja) * 1988-06-22 1998-01-21 大正製薬株式会社 被覆製剤
DE59000232D1 (de) * 1989-02-11 1992-09-10 Bayer Ag Arzneimittel mit kontrollierter wirkstoffabgabe.
US5292522A (en) * 1989-06-20 1994-03-08 Rohm Gmbh Aqueous film coating agent for solid medicaments
DK0524180T3 (da) 1990-04-11 1995-09-04 Upjohn Co Smagsmaskering af ibuprofen ved fluid bedovertrækning
US5288505A (en) 1991-06-26 1994-02-22 Galephar P.R., Inc., Ltd. Extended release form of diltiazem
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5376384A (en) * 1992-12-23 1994-12-27 Kinaform Technology, Inc. Delayed, sustained-release pharmaceutical preparation
NZ260408A (en) * 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
WO1996010996A1 (en) * 1993-07-21 1996-04-18 The University Of Kentucky Research Foundation A multicompartment hard capsule with control release properties
US5458888A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
US5733575A (en) * 1994-10-07 1998-03-31 Bpsi Holdings, Inc. Enteric film coating compositions, method of coating therewith, and coated forms
US5871776A (en) 1995-01-31 1999-02-16 Mehta; Atul M. Controlled-release nifedipine
DE19615812A1 (de) 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
DE19630035A1 (de) * 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
AU5310898A (en) 1996-12-20 1998-07-17 Dumex-Alpharma A/S Release-controlled coated tablets
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US5788987A (en) 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
PT1009387E (pt) * 1997-07-02 2006-08-31 Euro Celtique Sa Formulacoes estabilizadas de libertacao controlada de tramadol
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
AU738804B2 (en) * 1997-12-08 2001-09-27 Bristol-Myers Squibb Company Novel salts of metformin and method
US6022554A (en) * 1997-12-15 2000-02-08 American Home Products Corporation Polymeric microporous film coated subcutaneous implant
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6156342A (en) 1998-05-26 2000-12-05 Andex Pharmaceuticals, Inc. Controlled release oral dosage form
DE19826517B4 (de) 1998-06-15 2006-03-23 Baxter Healthcare S.A. Verfahren zur Herstellung von Filmtabletten mit Cyclophosphamid als Wirkstoff und daraus hergestellte Cyclophosphamid-Filmtablette
ES2206868T3 (es) * 1998-07-15 2004-05-16 Merck Sante Comprimidos que comprenden una combinacion de metformin glibenclamida.
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
DE19901686A1 (de) * 1999-01-18 2000-07-20 Gruenenthal Gmbh Retardierte Tramadolzubereitungen mit einem lagerstabilen Freisetzungsprofil und Verfahren zu deren Herstellung
IN191482B (da) 1999-03-19 2003-12-06 Ranbaxy Lab Ltd
US6183779B1 (en) * 1999-03-22 2001-02-06 Pharmascience Inc. Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin
DE19940740A1 (de) * 1999-08-31 2001-03-01 Gruenenthal Gmbh Pharmazeutische Salze
ES2226886T3 (es) * 1999-08-31 2005-04-01 Grunenthal Gmbh Forma de administracion de accion retardada que contiene sacarinato de tramadol.
WO2001045668A2 (en) * 1999-12-20 2001-06-28 Schering Corporation Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
US6419956B1 (en) 1999-12-30 2002-07-16 Ancile Pharmaceuticals Odor-masking coating for a pharmaceutical preparation
DE60123384T2 (de) * 2000-02-04 2007-08-02 DepoMed, Inc., Menlo Park Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6676966B1 (en) * 2000-05-09 2004-01-13 Intellipharmaceutics Corp. Extended release metformin hydrochloride formulations
IN192159B (da) * 2000-05-15 2004-02-28 Ranbaxy Lab Ltd
US6620439B1 (en) * 2000-10-03 2003-09-16 Atul M. Mehta Chrono delivery formulations and method of use thereof
US6866866B1 (en) * 2000-11-03 2005-03-15 Andrx Labs, Llc Controlled release metformin compositions
US6749867B2 (en) 2000-11-29 2004-06-15 Joseph R. Robinson Delivery system for omeprazole and its salts
SE0100200D0 (sv) * 2001-01-24 2001-01-24 Astrazeneca Ab New film coating
ITMI20010220A1 (it) 2001-02-05 2002-08-05 Valpharma Sa Formulazioni multiparticolate per somministrazione orale di sali di litio idonee per una somministrazione al giorno
NZ527930A (en) 2001-03-16 2005-11-25 Andrx Pharmaceuticals Llc Controlled release sulfonylurea formulation
US7858118B2 (en) * 2001-04-11 2010-12-28 Galephar Pharmaceutical Research, Inc. Extended release composition containing Tramadol
JP5138856B2 (ja) * 2001-06-20 2013-02-06 武田薬品工業株式会社 錠剤の製造方法
NZ532096A (en) * 2001-09-28 2006-10-27 Mcneil Ppc Inc Dosage forms having an inner core and outer shell with different shapes
US20040126428A1 (en) * 2001-11-02 2004-07-01 Lyn Hughes Pharmaceutical formulation including a resinate and an aversive agent
US6723348B2 (en) 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
US20030118647A1 (en) * 2001-12-04 2003-06-26 Pawan Seth Extended release tablet of metformin
US6667054B2 (en) * 2001-12-05 2003-12-23 Bernard Charles Sherman Metformin hydrochloride tablets
TWI252111B (en) * 2001-12-14 2006-04-01 Solvay Pharm Gmbh Matrix film tablet with controlled release of a natural mixture of conjugated estrogens
EP1355633B1 (en) 2001-12-19 2005-01-19 AstraZeneca AB NEW FILM COATING containing an ethyl acrylate/methyl methacrylate copolymer and polyvinyl acetate
EP1474123A1 (en) * 2002-01-03 2004-11-10 LEK Pharmaceuticals D.D. Controlled release pharmaceutical formulation containing venlafaxine
JP2003290319A (ja) * 2002-01-30 2003-10-14 Takeda Chem Ind Ltd 錠剤の製造装置
MXPA04008100A (es) * 2002-02-21 2005-06-17 Biovail Lab Int Srl Formulaciones de liberacion modificada de al menos una forma de tramadol.
US20040005358A1 (en) 2002-04-23 2004-01-08 Slugg Peter H. Modified-release vasopeptidase inhibitor formulation, combinations and method
US6902746B2 (en) 2002-07-03 2005-06-07 Yung Shin Pharmaceutical Industrial Co., Ltd. Oral pharmaceutical compositions containing non-steroidal anti-inflammatory drugs and method for preparing the same
SE0202353D0 (sv) * 2002-08-01 2002-08-01 Astrazeneca Ab New film coating
US7429619B2 (en) 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
US8216609B2 (en) * 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US7018658B2 (en) * 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin
DE10260919A1 (de) 2002-12-20 2004-07-01 Röhm GmbH & Co. KG Verfahren zur Herstellung von überzogenen Arzneiformen und Nahrungsergänzungsmitteln mit Konzentrationsgradienten im Überzug
US20040185097A1 (en) * 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
US20050048118A1 (en) * 2003-07-25 2005-03-03 Joan Cucala Escoi Modified release venlafaxine hydrochloride tablets
US20050025829A1 (en) * 2003-07-29 2005-02-03 Kim Cherng-Ju Controlled drug release tablets
US20050123596A1 (en) * 2003-09-23 2005-06-09 Kohane Daniel S. pH-triggered microparticles
EP1523981A1 (en) * 2003-10-13 2005-04-20 Wyeth Extended release formulations of venlafaxine
US20050084531A1 (en) * 2003-10-16 2005-04-21 Jatin Desai Tablet with aqueous-based sustained release coating
US7671094B2 (en) * 2005-06-27 2010-03-02 Biovail Laboratories International S.R.L. Bupropion hydrobromide and therapeutic applications
ZA200711123B (en) * 2005-06-27 2009-08-26 Biovail Lab Int Srl Modified-release formulations of a bupropion salt

Also Published As

Publication number Publication date
SI1476138T1 (sl) 2012-07-31
JP4704685B2 (ja) 2011-06-15
WO2003072089A1 (en) 2003-09-04
US20130245154A1 (en) 2013-09-19
EP1476139B1 (en) 2017-05-17
JP2010155864A (ja) 2010-07-15
CA2476201A1 (en) 2003-09-04
AU2003211145B2 (en) 2007-07-12
AU2003211146A1 (en) 2003-09-09
JP5069395B2 (ja) 2012-11-07
EP1476138B1 (en) 2011-12-07
CA2476496C (en) 2009-12-15
US20150030675A1 (en) 2015-01-29
ES2627842T3 (es) 2017-07-31
CA2476496A1 (en) 2003-09-04
ES2377729T3 (es) 2012-03-30
JP2005526047A (ja) 2005-09-02
CY1112517T1 (el) 2015-12-09
MXPA04008164A (es) 2005-05-17
US20080274177A1 (en) 2008-11-06
NO20043913L (no) 2004-11-16
WO2003072025A3 (en) 2003-11-06
AU2003211146B2 (en) 2007-07-19
PT1476138E (pt) 2012-02-14
ATE536173T1 (de) 2011-12-15
US20040037883A1 (en) 2004-02-26
MXPA04008100A (es) 2005-06-17
EP1476139A4 (en) 2007-12-26
EP1476138A2 (en) 2004-11-17
US7780987B2 (en) 2010-08-24
EP1476138B8 (en) 2012-03-07
AU2003211145A1 (en) 2003-09-09
JP2005526043A (ja) 2005-09-02
NZ535455A (en) 2009-08-28
EP1476138A4 (en) 2008-05-07
WO2003072025A2 (en) 2003-09-04
NZ535456A (en) 2006-08-31
CA2476201C (en) 2009-09-01
EP1476139A1 (en) 2004-11-17

Similar Documents

Publication Publication Date Title
DK1476138T3 (da) Formuleringer med modificeret frigivelse af mindst én form af tramadol
WO2010064126A3 (en) Controlled release dosage forms
DK1412384T3 (da) Stabil formulering af modificeret GLP-1
DK1401501T3 (da) Orale farmaceutiske sammensætninger med modificeret frigivelse af den aktive ingrediens
BR9914251A (pt) Formulações orais de liberação sustentada
EE200100670A (et) Amiidasendatud imidasokinoliinid
MEP33808A (hr) Farmaceutske kompozicije koje obuhvataju inhibitor hmg reduktaze
NO20015502L (no) Sulfonamid- og sulfamidsubstituerte imidazokinoliner
MXPA04002167A (es) Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
ATE334663T1 (de) Arzneimittelzusammensetzung mit verzögerter wirkstoffabgabe
PL371934A1 (en) Polymeric microemulsions
WO2002046188A3 (en) Amido ether substituted imidazoquinolines
HRP20020158B1 (en) Action of synergistic combination
DK1363641T3 (da) Progestagen, der er co-mikroniseret med et overfladeaktivt middel, farmaceutisk præparat, som indeholder det, fremgangsmåder til fremstilling deraf samt anvendelser deraf
HUP0401984A3 (en) Use of type 4 phosphodiesterase inhibitors for preparation of pharmaceutical compositions and combination with other active ingredients
CY1110906T1 (el) Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης
EP1389137A4 (en) COMPOSITIONS FOR THE RELEASE OF PROTEIN ON THE PULMONARY WAY
HRP20080297T3 (en) Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol
DK1399133T4 (da) Sammensætning med langvarig frigivelse omfattende mælkesyre-glykolsyre-copolymer samt fremgangsmåde til fremstilling heraf
BRPI0309651B8 (pt) método para prevenir ou reduzir a resistência a um pesticida de uma peste de substrato, composição de pesticida, uso dos mesmos, e, método para preparar uma composição de pesticida
ATE454385T1 (de) Hiv-integrase-hemmers, pharmazeutischen zusammensetzung und ihre anwendung
EP1600441A3 (en) Novel crystalline form of lercanidipin hydrochloride and processes for its preparation
ITMI20011338A0 (it) Composizioni farmaceutiche orali a rilascio immediato del principio attivo
CL2003002356A1 (es) Compuestos derivados de 1-(1-acetil-piperidin-4-il)-(ester o amida)-4-(bencidrilo sustituido)-2-tert-butil-piperazina, composicion farmaceutica, y su uso en la inhibicion de 17b-hidroxiesteroide deshidrogenasa de tipo 3 y de enfermedades que dependen
AU2001227030A1 (en) Pharmaceutical composition for controlled release of an active ingredient